Ayrton Capital’s Revelation Biosciences Warrant REVBW Stock Holding History

Ayrton Capital’s Portfolio REVBW Stock Details REVBW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$1.27K	Hold	75,000	–	–	0.01%	67
2023 Q2	$1.33K	Hold	75,000	–	–	0.01%	71
2023 Q1	$1.22K	Hold	75,000	–	–	﹤0.01%	83
2022 Q4	$983	Hold	75,000	–	–	﹤0.01%	91
2022 Q3	$3K	Hold	75,000	–	–	0.01%	104
2022 Q2	$6K	Hold	75,000	–	–	0.01%	99
2022 Q1	$10K	Hold	75,000	–	–	0.01%	112
2021 Q4	$51K	Buy	+75,000	New	+$46K	0.05%	80

Other funds holding REVBW

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

PVI

Pine Valley Investments Marlton, New Jersey $2.53B AUM 36.18% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Ayrton Capital's REVBW Position: Q3 2023 in Review

Ayrton Capital held its Revelation Biosciences Warrant (REVBW) position steady in Q3 2023 at 75,000 shares worth $1.27K. The position accounts for 0.01% of the portfolio, ranked #67.

Ayrton Capital first reported a position in REVBW in Q4 2021 and has held it in 8 quarters since. The position peaked at $51K in Q4 2021. 14 funds tracked by Wall St. Rank hold REVBW as of Q3 2023.

Ayrton Capital held 75,000 shares of Revelation Biosciences Warrant worth $1.27K as of Q3 2023.
Ayrton Capital left its Revelation Biosciences Warrant share count unchanged in Q3 2023.
Revelation Biosciences Warrant made up 0.01% of Ayrton Capital's portfolio in Q3 2023, its #67 holding.
Ayrton Capital first reported a position in Revelation Biosciences Warrant in Q4 2021 and has held it in 8 quarters since.
Ayrton Capital's Revelation Biosciences Warrant position peaked at $51K in Q4 2021.
14 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q3 2023.

Based on Ayrton Capital's 13F filing for Q3 2023, filed 13 Nov 2023.